5 recruiting, 3 active not recruiting, 3 withdrawn, 2 unknown. 7 Phase 2, 5 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Unknown 2, Withdrawn 2, Active not recruiting 1, Completed 1, Not yet recruiting 1 |
| Phase 1 | 5 | Active not recruiting 3, Recruiting 1, Withdrawn 1 |
| Phase 3 | 2 | Recruiting 2 |
Follow Unresectable Colorectal Carcinoma: new trials by email Literature Review of Unresectable Colorectal Carcinoma trials Research Report on Unresectable Colorectal Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma Aldesleukin, Biopsy, Biospecimen Collection - Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2025-12-05 | 2025-12-24 | |
| Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) Biopsy, Pembrolizumab, Therapeutic Autologous Dendritic Cells - Metastatic Microsatellite Stable Colorectal Carcinoma, Recurrent Colorectal Carcinoma | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2024-10-01 | 2024-09-26 | |
| Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial Bevacizumab, Capecitabine, Cetuximab - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 408 | 2024-04-10 | 2026-09-24 |
| LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Recruiting | University of Rochester | 800 | 2023-12-04 | 2026-01-09 | |
| Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2023-11-08 | 2026-09-29 |
| Understanding New Cachexia Subtypes Through Observational Epidemiological Research Biospecimen Collection, Computed Tomography, Electronic health record review - Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Recruiting | Kaiser Permanente | 800 | 2023-04-05 | 2026-08-20 | |
| Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer Pembrolizumab, Questionnaire Administration, Rintatolimod - Metastatic Colorectal Adenocarcinoma, Microsatellite Stable | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2022-02-01 | 2022-02-08 | |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Biopsy Procedure, Biospecimen Collection, Ceralasertib - Advanced Breast Carcinoma, Advanced Colon Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 51 | 2021-08-09 | 2026-09-04 |
| LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer Abemaciclib, Cetuximab, ERK1/2 Inhibitor LY3214996 - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 46 | 2020-12-02 | 2026-10-05 |
| Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations Pemigatinib, Quality-of-Life Assessment - FGFR1 Gene Amplification, FGFR1 Gene Mutation | Phase 2 | Unknown | Academic and Community Cancer Research United | 14 | 2020-08-31 | 2024-02-21 |
| Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer Panitumumab, Quality-of-Life Assessment, Questionnaire Administration - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 2 | Unknown | Academic and Community Cancer Research United | 12 | 2020-04-24 | 2024-05-21 |
| TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study Irinotecan, Bevacizumab, Trifluridine and Tipiracil Hydrochloride - Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 42 | 2019-12-27 | 2026-02-10 |
| M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Berzosertib, Biopsy Specimen, Biospecimen Collection - Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 66 | 2016-07-22 | 2026-09-25 |
Colorectal Neoplasms (15) · Neoplasm Metastasis (5) · Colonic Neoplasms (4) · Lung Neoplasms (4) · Pancreatic Neoplasms (4) · Rectal Neoplasms (3) · Carcinoma, Renal Cell (2) · Melanoma (2) · Uterine Cervical Neoplasms (2) · Appendiceal Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Basal Cell (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1)
Colonic Diseases (14) · Digestive System Diseases (14) · Digestive System Neoplasms (14) · Gastrointestinal Diseases (14) · Gastrointestinal Neoplasms (14) · Intestinal Diseases (14) · Intestinal Neoplasms (14) · Neoplasms (14) · Neoplasms by Site (14) · Rectal Diseases (14) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Neoplastic Processes (5) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3)
Magnetic Resonance Spectroscopy (8) · Specimen Handling (8) · Biopsy (5) · Irinotecan (4) · Bevacizumab (3) · Disulfides (3) · Capecitabine (2) · Cetuximab (2) · Exercise Test (2) · Fluorouracil (2) · Immunoglobulin G (2) · Leucovorin (2) · Panitumumab (2) · Trifluridine (2) · dehydroftorafur (2)
National Cancer Institute (NCI) (3) · Roswell Park Cancer Institute (3) · Academic and Community Cancer Research United (2) · City of Hope Medical Center (2) · ECOG-ACRIN Cancer Research Group (1) · Fred Hutchinson Cancer Center (1) · Kaiser Permanente (1) · M.D. Anderson Cancer Center (1) · University of Rochester (1)
United States (13) · Uganda (1)
Christos Fountzilas, MD (2) · Anwaar Saeed (1) · Christine M Parseghian, MD (1) · John H Strickler (1) · Kanwal P Raghav (1) · Kristen K Ciombor (1) · Liza C Villaruz (1) · Michael Lidsky (1) · Mustafa Raoof (1) · Richard F Dunne (1) · Sarbajit Mukherjee (1) · Shailender Bhatia, MD (1) · Vincent Chung (1)
P30CA015083 (2), P30CA033572 (2), UM1CA186690 (2), OT2CA278691 (1), R01CA187238 (1), U10CA180820 (1), UG1CA189961 (1), UM1CA186688 (1), UM1CA186689 (1), UM1CA186704 (1), UM1CA186717 (1)